IFIT2

Summary

IFIT2 (interferon induced protein with tetratricopeptide repeats 2, HGNC:5409) is a protein-coding gene on chromosome 10q23.31, encoding Interferon-induced protein with tetratricopeptide repeats 2 (P09913). IFN-induced antiviral protein which inhibits expression of viral messenger RNAs lacking 2’-O-methylation of the 5’ cap.

Enables RNA binding activity. Involved in antiviral innate immune response and positive regulation of apoptotic process. Located in endoplasmic reticulum.

Source: NCBI Gene 3433 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 59 total
• MANE Select transcript: NM_001547

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5409
Approved symbol	IFIT2
Name	interferon induced protein with tetratricopeptide repeats 2
Location	10q23.31
Locus type	gene with protein product
Status	Approved
Aliases	IFI-54, ISG-54K, ISG-54, cig42, GARG-39
Ensembl gene	ENSG00000119922
Ensembl biotype	protein_coding
OMIM	147040
Entrez	3433

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 9 protein_coding, 5 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000371826, ENST00000611722, ENST00000638108, ENST00000679606, ENST00000679608, ENST00000679619, ENST00000679734, ENST00000679755, ENST00000680381, ENST00000680558, ENST00000680809, ENST00000680954, ENST00000681150, ENST00000681843, ENST00000681850

RefSeq mRNA: 1 — MANE Select: NM_001547 NM_001547

CCDS: CCDS41548

Canonical transcript exons

ENST00000371826 — 2 exons

Exon	Start	End
ENSE00001456236	89305962	89309271
ENSE00003730418	89302046	89302128

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 94.59.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 75.9421 / max 14348.2540, expressed in 1184 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106108	74.5990	1109
106111	0.3017	86
106100	0.2055	94
106123	0.1663	72
106121	0.1659	73
106119	0.1500	62
106101	0.0928	37
106109	0.0842	22
106112	0.0652	37
106122	0.0608	40

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
palpebral conjunctiva	UBERON:0001812	94.59	gold quality
inferior vagus X ganglion	UBERON:0005363	94.52	gold quality
trigeminal ganglion	UBERON:0001675	94.17	gold quality
subthalamic nucleus	UBERON:0001906	93.23	gold quality
visceral pleura	UBERON:0002401	91.95	gold quality
leukocyte	CL:0000738	91.45	gold quality
monocyte	CL:0000576	91.40	gold quality
lateral globus pallidus	UBERON:0002476	91.38	gold quality
mononuclear cell	CL:0000842	91.26	gold quality
parietal pleura	UBERON:0002400	90.97	gold quality
dorsal root ganglion	UBERON:0000044	90.87	gold quality
pleura	UBERON:0000977	90.19	gold quality
superior vestibular nucleus	UBERON:0007227	90.16	gold quality
jejunal mucosa	UBERON:0000399	90.11	gold quality
blood	UBERON:0000178	89.86	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	89.72	gold quality
corpus callosum	UBERON:0002336	89.64	gold quality
spinal cord	UBERON:0002240	89.52	gold quality
germinal epithelium of ovary	UBERON:0001304	89.49	gold quality
ventral tegmental area	UBERON:0002691	88.49	gold quality
dorsal plus ventral thalamus	UBERON:0001897	88.31	gold quality
pons	UBERON:0000988	88.28	gold quality
pericardium	UBERON:0002407	88.26	gold quality
globus pallidus	UBERON:0001875	88.16	gold quality
epithelium of nasopharynx	UBERON:0001951	88.15	gold quality
substantia nigra pars reticulata	UBERON:0001966	88.01	gold quality
granulocyte	CL:0000094	87.94	gold quality
medial globus pallidus	UBERON:0002477	87.26	gold quality
medulla oblongata	UBERON:0001896	85.96	gold quality
tibia	UBERON:0000979	85.67	gold quality

Single-cell (SCXA)

Detected in 10 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-MTAB-7052	yes	35356.34
E-MTAB-7037	yes	15391.33
E-CURD-53	yes	4516.32
E-MTAB-10662	yes	944.63
E-MTAB-9388	yes	456.08
E-HCAD-4	yes	45.90
E-HCAD-13	yes	23.43
E-GEOD-106540	no	2084.37
E-GEOD-109979	no	209.65
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): IRF3, IRF6, PTPN22, STAT1, STAT2

miRNA regulators (miRDB)

78 targeting IFIT2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4715-3P	99.98	66.03	670
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-221-3P	99.86	71.56	1329
HSA-MIR-222-3P	99.86	71.35	1337
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107

Literature-anchored findings (GeneRIF, showing 25)

• The expression of interferon-induced genes IFI-54K and IFI-56K in the infected cells was found to increase 50-100-fold (PMID:12708317)
• We observed that, although double-stranded RNA or Sendai virus infection induced the two genes with similar kinetics, their induction kinetics in response to interferon-beta were quite different. (PMID:16973618)
• IFIT2/GARG39 was identified as a microtubule-associated protein enriched in the mitotic spindle of mouse NIH3T3 and B16F10 melanoma cells. (PMID:17030862)
• IFN-induced protein with tetratricopeptide repeats 2 inhibits migration activity and increases survival of oral squamous cell carcinoma. (PMID:18819931)
• The expression of OASL and IFIT2 was significantly higher in SLE patients than in controls. (PMID:20506645)
• role of ISG54 in the induction of apoptosis via a mitochondrial pathway shedding new light on the mechanism by which IFN elicits anti-viral and anti-cancer effects (PMID:21190939)
• Inhibitor of kappaB kinase epsilon (IKK(epsilon)), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection. (PMID:22065572)
• ISG54 binds specifically to some RNAs, such as adenylate uridylate (AU)-rich RNAs, with or without 5’ triphosphorylation. (PMID:22825553)
• IFIT2, a protein responsible for interferon stimulation, may prevent oral squamous cell carcinoma (OSCC) metastasis and serve as a valuable prognostic marker. (PMID:22986528)
• Data show that interferon-induced proteins with tetratricopeptide repeats 1 and 2 (IFIT1 and IFIT2) contribute to the regulation of hepatitis B virus (HBV) replication, likely at both transcriptional and posttranscriptional steps. (PMID:23867918)
• Data shows that IFIT2 expression is downregulated in adenocarcinoma of gastric esophageal junction cells; its ectopic expression leads to cell apoptosis, suggesting its role as a tumor suppressor. (PMID:25174799)
• there is a positive feedback loop between phosphorylated STAT1 and ISG56, ISG54 or ISG60. (PMID:26423178)
• LINC00161 is an essential regulator in cisplatin-induced apoptosis, and the LINC00161-miR-645-IFIT2 signalling axis plays an important role in reducing osteosarcoma chemoresistance. (PMID:27609068)
• Mechanistic investigations reveal that AJUBA specifically binds the FERM domain of JAK1 to dissociate JAK1 from the IFNgamma recepter, resulting in an inhibition of STAT1 phosporylation and concomitantly its nuclear translocation. Clinically, the level of AJUBA in CRC specimens is negatively correlated with the levels of IFIT2 and pSTAT1 (PMID:27893714)
• The results of the present study revealed that the inhibition of proteasome activity blocked the degradation of IFIT2 and promoted the aggregation of IFIT2 in the centrosome, which in turn induced cell apoptosis. In short, IFIT2 may be a potential target for cancer therapeutics. (PMID:28367102)
• These studies indicated PLZF inhibited the proliferation and metastasis via regulation of IFIT2. (PMID:29358655)
• IFIT2 and IFIT3 stabilize IFIT1 expression. (PMID:29554348)
• Studied effect of baicalein on gene expression in human breast cancer cell line and found baicalein reduced stem cell-like properties of the cells and induced apoptosis through up-regulation of IFIT2. (PMID:30875792)
• Overexpression of IFIT2 inhibits the proliferation of chronic myeloid leukemia cells by regulating the BCRABL/AKT/mTOR pathway. (PMID:32124954)
• Influenza virus repurposes the antiviral protein IFIT2 to promote translation of viral mRNAs. (PMID:32839537)
• Super-enhancer-associated long noncoding RNA RP11-569A11.1 inhibited cell progression and metastasis by regulating IFIT2 in colorectal cancer. (PMID:33942366)
• PML-II regulates ERK and AKT signal activation and IFNalpha-induced cell death. (PMID:34215258)
• Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma. (PMID:34763233)
• Identified Three Interferon Induced Proteins as Novel Biomarkers of Human Ischemic Cardiomyopathy. (PMID:34884921)
• MiR-199a-5P promotes osteogenic differentiation of human stem cells from apical papilla via targeting IFIT2 in apical periodontitis. (PMID:37063854)

Cross-species orthologs

10 orthologs

Organism	Symbol	Gene ID
danio_rerio	ifit10	ENSDARG00000007467
danio_rerio	ifit15	ENSDARG00000043584
danio_rerio	ifit16	ENSDARG00000056976
danio_rerio	ifit8	ENSDARG00000057173
danio_rerio	ifit14	ENSDARG00000071012
danio_rerio		ENSDARG00000088069
danio_rerio	ifit11	ENSDARG00000090537
danio_rerio	ifit12	ENSDARG00000090977
mus_musculus	Ifit2	ENSMUSG00000045932
rattus_norvegicus	Ifit2	ENSRNOG00000036604

Paralogs (4): IFIT3 (ENSG00000119917), IFIT5 (ENSG00000152778), IFIT1 (ENSG00000185745), IFIT1B (ENSG00000204010)

Protein

Protein identifiers

Interferon-induced protein with tetratricopeptide repeats 2 — P09913 (reviewed: P09913)

Alternative names: ISG-54 K, Interferon-induced 54 kDa protein

All UniProt accessions (5): P09913, A0A087X279, A0A7P0T8B3, A0A7P0T8R6, A0A7P0TAT2

UniProt curated annotations — full annotation on UniProt →

Function. IFN-induced antiviral protein which inhibits expression of viral messenger RNAs lacking 2’-O-methylation of the 5’ cap. The ribose 2’-O-methylation would provide a molecular signature to distinguish between self and non-self mRNAs by the host during viral infection. Viruses evolved several ways to evade this restriction system such as encoding their own 2’-O-methylase for their mRNAs or by stealing host cap containing the 2’-O-methylation (cap snatching mechanism). Binds AU-rich viral RNAs, with or without 5’ triphosphorylation, RNA-binding is required for antiviral activity. Can promote apoptosis.

Subunit / interactions. Domain-swapped homodimer. Component of an interferon-dependent multiprotein complex, at least composed of IFIT1, IFIT2 and IFIT3. Interacts with IFIT1 and IFIT3. Interacts with STING1/MITA and disrupts its interaction with MAVS or TBK1. Interacts with EIF3E and EIF3C.

Subcellular location. Cytoplasm. Endoplasmic reticulum.

Domain organisation. The C-terminal part folds into a super-helical structure and has an extensively positively-charged nucleotide-binding channel on its inner surface.

Induction. By type I interferons, dsRNAs and viruses.

Similarity. Belongs to the IFIT family.

RefSeq proteins (1): NP_001538* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011990	TPR-like_helical_dom_sf	Homologous_superfamily
IPR019734	TPR_rpt	Repeat

Pfam: PF13181

UniProt features (50 total): helix 24, repeat 9, mutagenesis site 5, turn 4, sequence variant 3, initiator methionine 1, chain 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4G1T	X-RAY DIFFRACTION	2.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P09913-F1	88.82	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Mutagenesis-validated functional residues (5):

Position	Phenotype
184	abolishes rna-binding.
255	significantly impairs rna-binding; when associated with glu-259.
259	significantly impairs rna-binding; when associated with glu-255.
292	abolishes rna-binding.
410	abolishes rna-binding.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-909733	Interferon alpha/beta signaling

MSigDB gene sets: 401 (showing top): BROWNE_HCMV_INFECTION_4HR_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, DORN_ADENOVIRUS_INFECTION_12HR_UP, GOZGIT_ESR1_TARGETS_DN, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, IRF7_01, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM3, DORN_ADENOVIRUS_INFECTION_32HR_UP, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6, DER_IFN_BETA_RESPONSE_UP

GO Biological Process (9): apoptotic mitochondrial changes (GO:0008637), response to virus (GO:0009615), positive regulation of apoptotic process (GO:0043065), defense response to virus (GO:0051607), antiviral innate immune response (GO:0140374), immune system process (GO:0002376), apoptotic process (GO:0006915), innate immune response (GO:0045087), response to other organism (GO:0051707)

GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (3): cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Interferon Signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
apoptotic process	2
cellular anatomical structure	2
cytoplasm	2
mitochondrion organization	1
response to other organism	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
defense response	1
response to virus	1
innate immune response	1
defense response to virus	1
biological_process	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
immune response	1
defense response to symbiont	1
response to external biotic stimulus	1
biological process involved in interspecies interaction between organisms	1
nucleic acid binding	1
binding	1
intracellular anatomical structure	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2573 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IFIT2	IFIT3	O14879	929
IFIT2	RIGI	O95786	903
IFIT2	IFIH1	Q9BYX4	880
IFIT2	ISG15	P05161	878
IFIT2	MX1	P20591	856
IFIT2	STAT1	P42224	851
IFIT2	OAS1	P00973	831
IFIT2	OASL	Q15646	822
IFIT2	IFI44	Q8TCB0	818
IFIT2	RSAD2	Q8WXG1	793
IFIT2	STAT2	P52630	789
IFIT2	IFITM3	Q01628	770
IFIT2	ISG20	Q96AZ6	766
IFIT2	CXCL10	P02778	742
IFIT2	OAS2	P29728	742

IntAct

18 interactions, top by confidence:

A	B	Type	Score
IFIT1	IFIT3	psi-mi:“MI:0914”(association)	0.920
IFIT2	IFIT3	psi-mi:“MI:0914”(association)	0.780
IFIT3	IFIT2	psi-mi:“MI:0915”(physical association)	0.780
IFIT2	IFIT1	psi-mi:“MI:0915”(physical association)	0.750
STING1	IFIT2	psi-mi:“MI:0915”(physical association)	0.560
STING1	IFIT2	psi-mi:“MI:0914”(association)	0.560
IFIT2	DNTTIP2	psi-mi:“MI:0915”(physical association)	0.400
	PABPC4	psi-mi:“MI:0914”(association)	0.350
rep	DDX3X	psi-mi:“MI:0914”(association)	0.350
IFIT3	HNRNPDL	psi-mi:“MI:0914”(association)	0.350
MAVS	IFIT3	psi-mi:“MI:0914”(association)	0.350

BioGRID (91): NUTM1 (Two-hybrid), IFIT3 (Two-hybrid), IFIT2 (Affinity Capture-MS), PHACTR4 (Affinity Capture-MS), IFIT1 (Affinity Capture-MS), HOMER3 (Affinity Capture-MS), IFIT3 (Affinity Capture-MS), BATF3 (Affinity Capture-MS), POLG2 (Affinity Capture-MS), RAB11B (Affinity Capture-MS), IFIT2 (Two-hybrid), IFIT2 (Affinity Capture-MS), IFIT2 (Affinity Capture-MS), IFIT2 (Affinity Capture-MS), IFIT2 (Two-hybrid)

ESM2 similar proteins: A1A5P5, A1L1K3, A7SUU7, B4JHK2, B4NKT1, E9Q6P5, F1QN74, P09913, P50748, Q0P5W1, Q14CX7, Q294E0, Q2KI89, Q32NR4, Q32PH0, Q3U0M1, Q4R6I5, Q4R6M4, Q5R629, Q5RE52, Q5U249, Q5ZKK3, Q60462, Q68F70, Q6AYP3, Q6PA97, Q6QI44, Q80VM3, Q86TV6, Q8BGB2, Q8BH74, Q8BTZ4, Q8BWZ3, Q8C0S4, Q8CIM8, Q8GZN1, Q8IYW2, Q8JGR7, Q8K368, Q8N3P4

Diamond homologs: A5A6J9, O14879, P09913, P09914, Q13325, Q4R5F5, Q5T764, Q60462, Q64112, Q64282, Q64345

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

59 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	51
Likely benign	5
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

149 predictions. Top by Δscore:

Variant	Effect	Δscore
10:89305960:A:AG	acceptor_gain	1.0000
10:89305961:G:GG	acceptor_gain	1.0000
10:89305958:A:AG	acceptor_gain	0.9900
10:89305958:ACAGT:A	acceptor_gain	0.9900
10:89305959:C:G	acceptor_gain	0.9900
10:89305959:CAG:C	acceptor_loss	0.9900
10:89305959:CAGTG:C	acceptor_gain	0.9900
10:89305960:A:AC	acceptor_loss	0.9900
10:89305960:AGT:A	acceptor_gain	0.9900
10:89305960:AGTGA:A	acceptor_gain	0.9900
10:89305961:G:GA	acceptor_loss	0.9900
10:89305961:GT:G	acceptor_gain	0.9900
10:89305961:GTG:G	acceptor_gain	0.9900
10:89305961:GTGA:G	acceptor_gain	0.9900
10:89305961:GTGAG:G	acceptor_gain	0.9900
10:89302129:GT:G	donor_loss	0.9800
10:89302104:C:G	donor_gain	0.9700
10:89302126:GAG:G	donor_gain	0.9600
10:89302125:TGAG:T	donor_gain	0.9200
10:89302126:G:GT	donor_gain	0.9200
10:89302129:G:GG	donor_gain	0.9200
10:89302124:ATGAG:A	donor_gain	0.8500
10:89302127:AG:A	donor_gain	0.8300
10:89302128:GG:G	donor_gain	0.8300
10:89305962:TG:T	acceptor_gain	0.7800
10:89302444:A:G	donor_gain	0.7000
10:89302608:A:G	donor_gain	0.6500
10:89305962:T:TA	acceptor_gain	0.6100
10:89308943:TGG:T	acceptor_gain	0.6000
10:89305947:T:TA	acceptor_gain	0.5900

AlphaMissense

3138 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:89306014:T:C	F20L	0.978
10:89306016:C:A	F20L	0.978
10:89306016:C:G	F20L	0.978
10:89307148:G:C	G398R	0.971
10:89306253:C:A	N99K	0.963
10:89306253:C:G	N99K	0.963
10:89307089:G:A	G378D	0.963
10:89307094:T:C	F380L	0.963
10:89307096:T:A	F380L	0.963
10:89307096:T:G	F380L	0.963
10:89306437:T:C	F161L	0.962
10:89306439:T:A	F161L	0.962
10:89306439:T:G	F161L	0.962
10:89306716:G:C	A254P	0.961
10:89306020:T:A	W22R	0.955
10:89306020:T:C	W22R	0.955
10:89306911:G:C	A319P	0.955
10:89306557:G:C	A201P	0.953
10:89306386:T:A	W144R	0.952
10:89306386:T:C	W144R	0.952
10:89306924:T:C	L323P	0.952
10:89307127:G:C	A391P	0.952
10:89307149:G:A	G398D	0.949
10:89306978:C:A	A341D	0.948
10:89306008:T:C	C18R	0.946
10:89306819:G:A	G288E	0.946
10:89307025:T:C	F357L	0.946
10:89307027:C:A	F357L	0.946
10:89307027:C:G	F357L	0.946
10:89306388:G:C	W144C	0.945

dbSNP variants (sampled 300 via entrez): RS1000666231 (10:89305208 G>A), RS1000773546 (10:89305844 G>C), RS1000839336 (10:89307595 G>A), RS1001122810 (10:89304040 G>A,C), RS1001486394 (10:89309658 T>C), RS1002122190 (10:89305745 C>T), RS1002262283 (10:89302435 C>G,T), RS1003231876 (10:89303798 G>A), RS1003304988 (10:89305099 G>A,C), RS1003371895 (10:89300858 G>A,T), RS1003518821 (10:89300310 A>G), RS1003693674 (10:89303974 C>T), RS1004054475 (10:89303951 T>A,C), RS1004408228 (10:89303731 C>T), RS1004616121 (10:89304369 G>A)

Disease associations

OMIM: gene MIM:147040 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

101 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases expression	3
monomethylarsonous acid	affects expression, decreases expression, increases expression	3
Tretinoin	decreases expression, increases expression	3
bisphenol A	increases expression, decreases methylation	2
sulforaphane	increases expression	2
Acetaminophen	decreases expression	2
Cisplatin	affects cotreatment, increases expression	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Formaldehyde	decreases expression, increases expression	2
Lipopolysaccharides	increases expression, affects cotreatment, decreases reaction	2
Poly I-C	affects cotreatment, decreases reaction, increases expression	2
Silicon Dioxide	increases expression	2
Valproic Acid	decreases expression, affects expression	2
Cyclosporine	decreases expression	2
Asbestos, Serpentine	decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
GSK-J4	increases expression	1
afuresertib	increases expression	1
takinib	decreases reaction, increases expression	1
PAM2-CSK4	affects reaction, decreases reaction, increases expression	1
TL8-506	affects cotreatment, increases expression	1
22-hydroxycholesterol	increases expression	1
ethylbenzene	increases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
arsenite	affects binding, increases reaction	1
butyraldehyde	decreases expression	1
perfluorooctanoic acid	decreases expression	1
tobacco tar	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1FV	Abcam A-549 IFIT2 KO 1	Cancer cell line	Male
CVCL_B2NE	Abcam A-549 IFIT2 KO 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.